Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): SL-401 in combination with HCVAD and VENETOCLAX
MD Anderson Study Status
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Mercaptopurine, Methotrexate, Methylprednisolone, Prednisone, Rituximab, Tagraxofusp-erzs, Venetoclax, Vincristine
This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant protein consisting of IL-3 linked to a toxic agent called DT. IL-3 attaches to IL-3 receptors on tumor cells in a targeted way and delivers DT to kill them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and SL-401 with chemotherapy may be an effective treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Blastic Plasmacytoid Dendritic Cell Neoplasm
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.